Highnoon Laboratories Limited (PSX:HINOON)

Market Cap	56.67B
Revenue (ttm)	26.61B
Net Income (ttm)	3.67B
Shares Out	52.98M
EPS (ttm)	69.33
PE Ratio	15.43
Forward PE	n/a
Dividend	40.00 (3.74%)
Ex-Dividend Date	Apr 18, 2025

Volume	15,683
Average Volume	11,623
Open	1,079.90
Previous Close	1,069.66
Day's Range	1,062.00 - 1,088.75
52-Week Range	793.00 - 1,241.00
Beta	-0.01
RSI	31.32
Earnings Date	Mar 25, 2026

About Highnoon Laboratories

Highnoon Laboratories Limited, together with its subsidiaries, manufactures, imports, sells, exports, and markets pharmaceutical and allied consumer products. It offers products in various therapeutic areas, including allergy, anti-infective, cardiology, gastroenterology, metabolic, musculoskeletal, obstetrics and gynaecology, paediatrics, allergy, respiratory, and urology; and generic products under various brands. The company operates in Pakistan, Afghanistan, the United Arab Emirates, France, Kenya, Iraq, Cambodia, Tanzania, Dubai, Sudan, an...

• Industry: Pharmaceuticals
• Sector: Healthcare
• Founded: 1984
• Employees: 2,376
• Stock Exchange: Pakistan Stock Exchange
• Ticker Symbol: HINOON

Financial Performance

In 2024, Highnoon Laboratories's revenue was 24.63 billion, an increase of 24.60% compared to the previous year's 19.77 billion. Earnings were 3.39 billion, an increase of 38.44%.